New Eye-Tracking tech could let AMD patients monitor vision loss from home

NCT ID NCT07255859

Recruiting now Diagnosis Sponsor: Tan Tock Seng Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a home-based eye-tracking system called AVIGA to see if it can detect when wet age-related macular degeneration (AMD) comes back. Sixty adults aged 50-99 who are being treated for wet AMD will use the AVIGA device at home, and its accuracy will be compared to the standard Amsler grid test. The goal is to make monitoring easier and more accessible for patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AVIGA device (home-based gaze-tracking system)
What this could lead to: If successful, this could provide a convenient, at-home way to monitor for wet AMD recurrence, potentially reducing the need for frequent clinic visits.
What could go wrong: This is a small, early-stage study (60 participants) focused on diagnostic accuracy. The device may not be as reliable as in-clinic tests, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MACULOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

choroidal neovascularization diabetic retinopathy macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MACULOPATHY

Contacts and locations

Locations

Tan Tock Seng Hospital
RECRUITING

Singapore, 308433, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.